<DOC>
	<DOCNO>NCT00821249</DOCNO>
	<brief_summary>This 2-phase study patient relapse refractory multiple myeloma ( MM ) plasma cell leukemia ( PCL ) , already receive least two previous treatment , receive investigational study drug ARRY-520 . The study 3 part . In first part study , Phase 1 , patient receive increase dos study drug , without granulocyte-colony stimulating factor ( G-CSF ) support , order achieve high dose possible cause unacceptable side effect . Approximately 30 patient US enrol Part 1 ( Active , recruit ) . In second part study , Phase 2 , patient receive best dose study drug determine first part study follow evaluate side effect study drug cause effectiveness , , treat cancer . Approximately 30 patient US enrol Part 2 ( Active , recruit ) . In third part study , Phase 2 Dexamethasone , patient receive best dose study drug determine first part study , combination dexamethasone , follow evaluate side effect combination cause effectiveness combination , , treat cancer . Approximately 50 patient US enrol Part 3 ( Active , recruit ) .</brief_summary>
	<brief_title>A Study ARRY-520 Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Key Inclusion Criteria ( Part 3 ) : Patients receive least two prior treatment regimen . Confirmed refractory MM ( measurable disease ) PCL . Patients must refractory treatment lenalidomide/dexamethasone bortezomib/dexamethasone ( treatment bortezomib/lenalidomide/dexamethasone ) , define document progressive disease therapy within 60 day complete treatment regimen . Previously receive adequate alkylator therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . Adequate hematology laboratory value without transfusion support within 2 week screen . Adequate liver renal function . Additional criterion exist . Key Exclusion Criteria ( Part 3 ) : Primary amyloidosis . Concomitant malignancies previous malignancy less 3year disease free interval time enrollment ( patient adequately resect basal squamous cell carcinoma skin , carcinoma situ cervix Stage A low grade prostate cancer may enroll irrespective time diagnosis ) . Autologous allogeneic stem cell bone marrow transplant within 3 month prior first dose study drug . Cytotoxic therapy monoclonal antibody within 21 day prior first dose study drug . Radiotherapy within 21 day prior first dose study drug ( radiation portal cover â‰¤ 5 % bone marrow reserve , patient may enrol irrespective end date radiotherapy ) . Corticosteroid dose &gt; 10 mg/day prednisone equivalent within 2 week prior first dose study drug . Known positive serology human immunodeficiency virus ( HIV ) , hepatitis B and/or active hepatitis C. Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>plasma cell dyscrasia</keyword>
	<keyword>plasmacytoma</keyword>
	<keyword>kinesin spindle protein</keyword>
	<keyword>anti-mitotic</keyword>
</DOC>